High-yield and high-throughput afucosylated mAb expression benefits therapeutic antibody efficacy

3 October 2022
sino_biological_large-2

*Sponsored content

The latest in a series of Industry Leader pieces from biological reagent supplier and service provider Sino Biological.

An absence of fucose residues on the antibody Immunoglobulin γ (IgG) constant (Fc) region N-glycan moiety has been demonstrated to increase the binding affinity to IgG-Fc-receptor (FcγR) IIIa. It results in increased antibody-dependent cellular cytotoxicity (ADCC) since this receptor is found on immune effector cells like natural killer cells. Sino Biological establishes a proprietary “FucoFree” eukaryotic cell culture system for the custom expression of afucosylated mAbs. We provide high-yield and high-throughput antibody expression with >95% purity and low endotoxin level (<1 EU/mg).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology